The treatment of Cholestasis & Hypoglycemia with vitamins

Cholestasis and Hypoglycemia: Mitamins custom make quality formulas for the treatment of Cholestasis & Hypoglycemia with vitamins. A Cholestasis & Hypoglycemia formula will be made to suit you, using quality brand name ingredients. Mitamins produce custom made vitamin and supplement formulas to suit your individual health needs conveniently in one formula, one bottle and one dosage. For assistance, call toll free: 1-866-585-1390
Your Supplements Facts - Covers the formulas above
Supplement Facts

Specially Formulated for: Cholestasis and Hypoglycemia

  • Amount Per Serving
    % DV
    Vitamin A
    2500
    IU
    50%
    Vitamin C
    100
    mg
    167%
    Vitamin E
    200
    IU
    667%
    Vitamin K
    10
    mcg
    13%
    Niacin
    50
    mg
    250%
    Chromium
    100
    mcg
    83%
    MSM
    100
    mg
    *
  • Amount Per Serving
    % DV
    SAMe
    400
    mg
    *
    American Ginseng Extract
    50
    mg
    *
    Milk Thistle Extract
    100
    mg
    *
    L-Glutamine
    100
    mg
    *
    Dandelion Extract
    100
    mg
    *
    * Daily Value (DV) not established
Name Your Supplement Bottle - Just how you like it
The current default name is: 
 
(Click in box to change)
Your Perfect Supplement - Custom-made just for you
Formulas form 35 Years of Medical Practice
Cholestasis and Hypoglycemia
Serving Size:4-5

Cholestasis and Hypoglycemia Formulas Details

Customize Your Supplements - Check all that apply
4A Select additional condition(s) you want to address:


4B Select all the medication(s) you are taking:
If your concern or medication is not listed here, use our Formulator, which covers 680 concerns and 1600 drugs, Click here!
Latest Health Related News:
World Alzheimer's Day Lecture And BMA Medical Book Competition Award, Scotland
Alzheimer Scotland will be holding its 7th Annual World Alzheimer's Day Lecture 'The Dementia Epidemic: is it inevitable?' at 6pm on Wednesday 19 September 2007 at Glasgow Caledonian University There is growing concern about the impact of demographic change on the number of people with dementia in Scotland, with a projected increase of 75% by 2031, which provides the focus for the lecture.
AlphaRx Announces Selection Of ARX828, A Novel INOS Inhibitor, For Advanced Preclinical Development
AlphaRx Inc. (OTC BB: ALRX), a specialty pharmaceutical company announced that its ARX828, an orally-administered, potent and selective inhibitor of iNOS (Inducible Nitric Oxide Synthase), is advancing to preclinical studies to support an investigational new drug (IND) application in 2008.
This information concerning the support of Cholestasis and Hypoglycemia treatments provide basic knowledge which should always be discussed with your own health practitioner.
Any Questions, Call Us Toll Free: 1-866-585-1390
Live Chat System

manufactured In USA

  verisign          Trust E Finalmark

Custom Vitamins and Nutritional Supplements for Supporting Age-Related Cognitive Decline and Aging Treatments